Peer-Reviewed Publication
J Neurooncol2026;179(3)September 16, 2026Journal Article
Quantitative stability of MGMT promoter methylation in recurrent glioma and implications for temozolomide rechallenge.
Henry Noren1, Gabriella Pelofsky2, Brianna Suffren3, Laura Mittelman3, Christine Yohn1, Aminah Twyman1, Christopher A Febres-Aldana4, Arevik Abramyan1, Aparna Sertil5, Randy S D'Amico3, Jonathan H Sherman1,6,7, Morana Vojnic8,9
1Department of Neurosurgery, Rutgers Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, NJ, 08901, USA.
2Department of Neurosurgery, Rutgers New Jersey Medical School, Newark, NJ, USA.
3Department of Neurosurgery, Lenox Hill Hospital, New York, NY, USA.
4Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
5Caris Life Sciences, Phoenix, AZ, USA.
6Rutgers Cancer Institute, New Brunswick, NJ, USA.
7RWJBarnabas Health, West Orange, NJ, USA.
8Rutgers Cancer Institute, New Brunswick, NJ, USA. mv858@cinj.rutgers.edu.
9RWJBarnabas Health, West Orange, NJ, USA. mv858@cinj.rutgers.edu.
Abstract
PURPOSE: O^6^-methylguanine-DNA methyltransferase (MGMT) promoter methylation is a key predictive biomarker for temozolomide (TMZ) response in glioma. MGMT status is routinely assessed at diagnosis; however, its utility at recurrence remains incompletely characterized. We aimed to quantify MGMT methylation stability and assess the clinical relevance of reported status changes in recurrent glioma.…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans